文献速递肾癌与肾肿瘤

转移性肾细胞癌一线治疗的动态交互式系统评价与网络Meta分析

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2021-04-03

网络Meta分析排序显示,卡博替尼联合纳武利尤单抗在客观缓解率、无进展生存期和总生存期上排名最高,而伊匹木单抗联合纳武利尤单抗在完全缓解率上排名最高,但卡博替尼联合纳武利尤单抗的治疗相关不良事件排名最低。

要点

  • 卡博替尼联合纳武利尤单抗在ORR、PFS和OS上排序最高,但治疗相关不良事件最多。
  • 伊匹木单抗联合纳武利尤单抗完全缓解率排序最高,且不良事件最少(与阿替利珠单抗联合贝伐珠单抗并列)。
  • 帕博利珠单抗联合阿昔替尼和伊匹木单抗联合纳武利尤单抗是可接受的替代方案,但后者可能不优选于 favorable risk 患者。

核心结论

  • 卡博替尼联合纳武利尤单抗可能引起更多不良事件,但在所有疗效结局上排序最佳,除外完全缓解率以伊匹木单抗联合纳武利尤单抗机会最大。
  • 帕博利珠单抗联合阿昔替尼和伊匹木单抗联合纳武利尤单抗是可接受的替代方案,但伊匹木单抗联合纳武利尤单抗可能不优选于 favorable risk 患者。
  • 网络Meta分析虽提供统计调整后的排序,但跨试验比较存在固有偏倚且直接证据稀疏,不能替代随机比较。

研究设计与样本

  • 研究为动态交互式系统评价与网络Meta分析,纳入比较当代一线治疗方案与单药酪氨酸激酶抑制剂的随机对照试验。

主要发现

  • 卡博替尼联合纳武利尤单抗在客观缓解率、无进展生存期和总生存期上排序最高。
  • 伊匹木单抗联合纳武利尤单抗在完全缓解率上排序最高。
  • 伊匹木单抗联合纳武利尤单抗与阿替利珠单抗联合贝伐珠单抗在治疗相关不良事件上排序最高(毒性最低),卡博替尼联合纳武利尤单抗排序最低。

临床怎么用

  • 该动态交互式系统评价提供多种一线治疗方案的获益、危害及证据 certainty 的交互式证据摘要,并随新研究发表更新。
  • 临床决策时可参考该动态交互式系统评价的排序结果,但需注意跨试验比较的固有偏倚,不能替代随机对照试验的直接比较。

局限性

  • 跨试验比较存在固有偏倚,且直接证据稀疏,网络Meta分析的排序不能替代随机比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Identifying the most effective first-line treatment for metastatic renal cell carcinoma (mRCC) is challenging as rapidly evolving data quickly outdate the existing body of evidence, and current approaches to presenting the evidence in user-friendly formats are fraught with limitations. OBJECTIVE: To maintain living evidence for contemporary first-line treatment for previously untreated mRCC. EVIDENCE ACQUISITION: We have created a living, interactive systematic review (LISR) and network meta-analysis for first-line treatment of mRCC using data from randomized controlled trials comparing contemporary treatment options with single-agent tyrosine kinase inhibitors. We applied an advanced programming and artificial intelligence-assisted framework for evidence synthesis to create a living search strategy, facilitate screening and data extraction using a graphical user interface, automate the frequentist network meta-analysis, and display results in an interactive manner. EVIDENCE SYNTHESIS: As of October 22, 2020, the LISR includes data from 14 clinical trials. Baseline characteristics are summarized in an interactive table. The cabozantinib + nivolumab combination (CaboNivo) is ranked the highest for the overall response rate, progression-free survival, and overall survival, whereas ipilimumab + nivolumab (NivoIpi) is ranked the highest for achieving a complete response (CR). NivoIpi, and atezolizumab + bevacizumab (AteBev) were ranked highest (lowest toxicity) and CaboNivo ranked lowest for treatment-related adverse events (AEs). Network meta-analysis results are summarized as interactive tables and plots, GRADE summary-of-findings tables, and evidence maps. CONCLUSIONS: This innovative living and interactive review provides the best current evidence on the comparative effectiveness of multiple treatment options for patients with untreated mRCC. Trial-level comparisons suggest that CaboNivo is likely to cause more AEs but is ranked best for all efficacy outcomes, except NivoIpi offers the best chance of CR. Pembrolizumab + axitinib and NivoIpi are acceptable alternatives, except NivoIpi may not be preferred for patients with favorable risk. Although network meta-analysis provides rankings with statistical adjustments, there are inherent biases in cross-trial comparisons with sparse direct evidence that does not replace randomized comparisons. PATIENT SUMMARY: It is challenging to decide the best option among the several treatment combinations of immunotherapy and targeted treatments for newly diagnosed metastatic kidney cancer. We have created interactive evidence summaries of multiple treatment options that present the benefits and harms and evidence certainty for patient-important outcomes. This evidence is updated as soon as new studies are published.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Riaz IB, He H, Ryu AJ, et al. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021. PMID: 33824031. doi:10.1016/j.eururo.2021.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。